On Demand Dissoluble Supramolecular Hydrogels: Towards Pain Free Burn Dressings
按需可溶性超分子水凝胶:迈向无痛烧伤敷料
基本信息
- 批准号:10658220
- 负责人:
- 金额:$ 48.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AccelerationAcuteAdamantaneAdoptionAdultAnesthesia proceduresAnimal ModelAnimalsAntibioticsAreaBacterial InfectionsBiocompatible MaterialsBurn injuryCaringCellsCessation of lifeChemicalsChemistryChildClinicClinicalCritical CareDataDebridementDevelopmentEconomicsElectric BurnsElectrostaticsEmergency department visitEmotionalEndothelial CellsEpitheliumEvaluationExcisionExposure toFaceFamilyFamily suidaeFibroblastsFire - disastersForeign-Body ReactionGenerationsGoalsGram-Negative BacteriaHistologyHourHumanHybridsHydrogel BandageHydrogelsImmuneImmune ToleranceImpaired healingIn VitroInbred BALB C MiceInfectionInfection preventionInflammatoryInflammatory ResponseInjuryIntensive Care UnitsInterleukin-6KineticsLength of StayLifeLymphocyteMacrophageMechanicsMethodsMissionModelingMultiple Organ FailureMusNational Institute of Arthritis, and Musculoskeletal, and Skin DiseasesNatural regenerationOperative Surgical ProceduresOpioidPainPain FreePatient CarePatientsPerformancePersonsPredispositionProceduresProcessPropertyRegenerative MedicineReportingReproducibilityRiskSepsisSilverSkinSodiumSterile coveringsStrategic PlanningSulfadiazineSurfaceSurvivorsSwellingTNF geneTestingTimeTissuesToxic effectTraumaUnited StatesWaterWound InfectionWound modelsantimicrobialaqueousbiomaterial compatibilityburn woundclayclinically relevantcopolymercostcrosslinkcytokinedesigndisabilityexperienceexperimental studyfallshealingimprovedin vitro Modelin vivoin vivo evaluationinfection managementkeratinocytemechanical propertiesnanosheetnovelopen woundpain reductionpediatric patientsphysical propertypolyacrylatepre-clinicalpsychologicrational designresponsesecond degree burnsevere burnsskin woundtissue repairwoundwound healing
项目摘要
Abstract
This proposal describes the synthesis, characterization, and thorough evaluation of the first
supramolecular hybrid hydrogel burn dressing. Our design goals are a) on-demand dissolubility -for easy
trauma-free removal from burn wound-, b) integrated antimicrobial activity - for infection management-,
and c) self-healing – for problem-free application and use. Burn injuries are one of the most prevalent,
devastating, and demanding critical care problems, worldwide. Nearly every minute, someone in the US
sustains a serious burn injury, and each day over 300 children visit emergency rooms and 2 of them die
due to burn injuries. Millions, globally, suffer from burn-related disabilities with heavy psychological,
emotional, and economic consequences on the survivors and their families. Burn dressing removal is
reportedly the time of most pain (after the burn itself), and opioids are the primary treatment for such
pain. The burn dressing change for a typical injury with intensive care unit level care is at least 57.6
minutes. The time and complexity of the process further grow with the frequently applied anesthesia.
Importantly, repeated painful dressing changes and wound infection cause a higher predisposition to life-
threatening sepsis and multi-organ failure. Currently available burn dressings – used clinically – adhere
to the wound surface and are surgically or mechanically debrided from the wound. This results in the
traumatization of newly epithelialized tissues, delayed healing and severe pain. We, thus, propose to
create a supramolecular hybrid hydrogel combining the host-guest chemistry (cucurbituril [7]-hosted
cationic copolymer) with inorganic components (i.e., clay) (Aim1). The unique feature of this hydrogel will
be its high biocompatibility and ability to be dissolved on-demand via adamantane/diamantane
derivatives, easily and quickly removed and eliminate debridement. This will reduce extreme pain and
suffering (by drastically reducing time of pain). The proposed hydrogel will also be embedded with
antibiotics to reduce bacterial infection. We will test this hydrogel through both in vitro (mouse and human
cells, Aim 2) and in vivo (mouse, Aim 3) and preclinical (swine, Aim 3) experiments. Overall, our goal is
to promote better burn wound healing, deter infection and provide pain-free burn care for patients, in line
with the mission of NIAMS. This project falls under the umbrella of regenerative medicine (wound healing,
tissue repair, regeneration) and treatment of large-area acute skin wounds (burns and trauma)
highlighted in the NIAMS Strategic Plan for FY 2020-2024. The project also focuses on a) improving the
patient experience (reducing pain), and b) treating co-occuring conditions of burn wounds and infections,
two focus areas of NIAMS.
抽象的
该建议描述了第一个的综合,表征和彻底评估
超分子混合水凝胶燃烧敷料。我们的设计目标是a)按需溶解性 - 简单
从烧伤伤口中无创伤 - b)综合抗菌活性 - 用于感染管理 -
c)自我修复 - 用于无问题的应用和使用。烧伤是最普遍的之一,
全球毁灭性的和要求重症监护问题。几乎每一分钟,美国的人
遭受严重的烧伤,每天有300多名儿童访问急诊室,其中2个死亡
由于烧伤。全球数以百万计
情感和经济后果对生存及其家人。烧伤敷料是
据报道,大多数疼痛的时间(在烧伤本身之后),阿片类药物是这样的主要治疗方法
疼痛。典型的重症监护仪护理典型伤害的燃烧调味料至少为57.6
分钟。该过程的时间和复杂性随着经常应用的麻醉而进一步增长。
重要的是,反复的疼痛敷料变化和伤口感染会导致寿命更高 -
威胁败血症和多器官失败。目前可用的燃烧敷料 - 临床上使用 - 粘附
到一眼,并通过手术或机械从伤口进行调试。这导致
新上皮组织的创伤,延迟愈合和剧烈疼痛。因此,我们建议
创建一种结合宿主 - 环化学的超分子杂化水凝胶(Cucurbituril [7] hosted
阳离子共聚物)与无机成分(即粘土)(AIM1)。该水凝胶的独特特征将
是其高生物相容性和通过阿甘坦烷/二氨烷溶解的能力
衍生品轻松快速地删除并消除调试。这将减轻极端疼痛和
痛苦(通过大大减少疼痛时间)。提出的水凝胶也将与
抗生素可减少细菌感染。我们将通过体外测试该水凝胶(小鼠和人类
细胞,AIM 2)和体内(小鼠,AIM 3)和临床前(猪,AIM 3)实验。总的来说,我们的目标是
为了促进更好的烧伤伤口愈合,确定感染并为患者提供无痛的烧伤护理
带有尼亚姆斯的任务。该项目属于再生医学的伞(伤口愈合,
组织修复,再生)和大区域急性皮肤伤口的治疗(烧伤和创伤)
在2020 - 2024财年的NIAMS战略计划中强调。该项目还侧重于a)改进
患者经历(减轻疼痛),b)治疗烧伤伤口和感染的共归因于
Niams的两个焦点区域。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Ayse Asatekin其他文献
Ayse Asatekin的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Ayse Asatekin', 18)}}的其他基金
Controlling biomicrofluidic device surface chemistry using smart surface-segregating zwitterionic polymers
使用智能表面隔离两性离子聚合物控制生物微流体装置表面化学
- 批准号:
10446995 - 财政年份:2021
- 资助金额:
$ 48.72万 - 项目类别:
Controlling biomicrofluidic device surface chemistry using smart surface-segregating zwitterionic polymers
使用智能表面隔离两性离子聚合物控制生物微流体装置表面化学
- 批准号:
10193245 - 财政年份:2021
- 资助金额:
$ 48.72万 - 项目类别:
相似国自然基金
阿魏酸基天然抗氧化抗炎纳米药物用于急性肾损伤诊疗一体化研究
- 批准号:82302281
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于hemin-MOFs的急性心肌梗塞标志物负背景光电化学-比色双模分析
- 批准号:22304039
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
RNA甲基转移酶NSUN2介导SCD1 mRNA m5C修饰调控急性髓系白血病细胞铁死亡的机制研究
- 批准号:82300173
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于IRF5/MYD88信号通路调控巨噬细胞M1极化探讨针刀刺营治疗急性扁桃体炎的机制研究
- 批准号:82360957
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:地区科学基金项目
相似海外基金
Novel, Self-Applied MicroArray Patch (MAP) of Zanamivir for Treatment of the Flu
用于治疗流感的新型扎那米韦自用微阵列贴片 (MAP)
- 批准号:
10761086 - 财政年份:2023
- 资助金额:
$ 48.72万 - 项目类别:
Synthetic Strategies to Restore the Efficacy of Venetoclax in Acute Myeloid Leukemia
恢复 Venetoclax 在急性髓系白血病中的疗效的综合策略
- 批准号:
10290284 - 财政年份:2021
- 资助金额:
$ 48.72万 - 项目类别:
Synthetic Strategies to Restore the Efficacy of Venetoclax in Acute Myeloid Leukemia
恢复 Venetoclax 在急性髓系白血病中的疗效的综合策略
- 批准号:
10457407 - 财政年份:2021
- 资助金额:
$ 48.72万 - 项目类别:
Microneedle Delivery of Zanamivir for the Treatment of Influenza Infections
扎那米韦微针治疗流感感染
- 批准号:
10614045 - 财政年份:2017
- 资助金额:
$ 48.72万 - 项目类别:
Microneedle Delivery of Zanamivir for Treatment of Influenza
扎那米韦微针治疗流感
- 批准号:
10132966 - 财政年份:2017
- 资助金额:
$ 48.72万 - 项目类别: